[ <sup>177</sup> Lu]Lu-AKIR001 for CD44v6-Positive Pancreatic Cancer: Preclinical Efficacy and Combination Strategies
Lu]Lu-AKIR001 demonstrated activity-dependent therapeutic potential in mice bearing PDAC xenografts. Combination therapy with paclitaxel indicated potential synergistic benefit, but further investigation and optimization are warranted.
Authors
- Å. Gustafsson
- Cecilia Lindskog (ORCID: https://orcid.org/0000-0001-5611-1015)
- Sara S. Rinne (ORCID: https://orcid.org/0000-0003-2141-3982)
- Ram Kumar Selvaraju (ORCID: https://orcid.org/0000-0001-9219-1497)
- Marika Nestor (ORCID: https://orcid.org/0000-0003-4662-3142)
- Filippa Bertilsson (ORCID: https://orcid.org/0009-0004-4243-5739)
- Hedvig Svedberg
- Anja C. Lundgren Mortensen
Institutions
- Uppsala University (SE)
- Science for Life Laboratory (SE)
- Karolinska Institutet (SE)
Publication Details
- Journal
- Journal of Nuclear Medicine
- Published
- 2026-04-22
- DOI
- https://doi.org/10.2967/jnumed.125.271705
- Primary Topic
- Proteoglycans and glycosaminoglycans research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Knut och Alice Wallenbergs Stiftelse
- Uppsala Universitet